OMNIVIUM PHARMACEUTICALS
Live / Registered — Registered (as of 03 Sept 2024)
What this means for you
Registered since 03 Sept 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90839896
- Registration number
- 7495809
- Mark type
- Design + words
- Filed
- 21 Jul 2021
- Published for opposition
- 27 Sept 2022
- Registered
- 03 Sept 2024
- Attorney of record
- Michael C. Cannata
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical products and preparations for curing, halting and preventing cardiovascular, bacterial, viral, psychiatric, eye, central nervous system, gastrointestinal, and cancer related diseases, easing symptoms, or helping in the diagnosis of illnesses; house mark for a full line of pharmaceuticals
Owner
- Omnivium Pharmaceuticals LLC, Rahway, NJ, US
- Omnivium Pharmaceuticals LLC, Rahway, NJ, US
- Omnivium Pharmaceuticals LLC, Rahway, NJ, US
Prosecution history
- 03 Sept 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 03 Sept 2024 — REGISTERED-PRINCIPAL REGISTER
- 31 Jul 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 31 Jul 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 30 Jul 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Jul 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 30 Jul 2024 — ASSIGNED TO LIE
- 09 Feb 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 28 Dec 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 28 Dec 2023 — NON-FINAL ACTION E-MAILED
- 28 Dec 2023 — SU - NON-FINAL ACTION - WRITTEN
- 05 Dec 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Nov 2023 — USE AMENDMENT FILED
- 05 Dec 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Nov 2023 — TEAS STATEMENT OF USE RECEIVED